Startuprad.io Launches Startup AI Concierge for Europe’s Startup Ecosystem

Startuprad.io today unveils the Startup AI Concierge, an AI-powered knowledge assistant that transforms how professionals in Europe's startup and innovation ecosystem access insight. Built on over a decade of interviews, analysis, and reporting, the Concierge brings verified, source-cited intelligence directly to founders, investors, and policymakers. https://mma.prnewswire.com/media/2799865/Startuprad_Logo.jpg From Media Platform to Knowledge InfrastructureWhen Startuprad.io launched, it […]

SNAP DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Snap Inc. Investors to Secure Counsel Before Important October 20 Deadline in Securities Class Action – SNAP

NEW YORK, NY, AL / ACCESS Newswire / October 19, 2025 / WHY: New York, N.Y., October 19, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Snap Inc. (NYSE:SNAP) between April 29, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), of the important October 20,

Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations are as follows: Late-Breaking Oral

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Freeport-McMoRan Inc. Investors to Inquire About Securities Class Action Investigation -FCX

NEW YORK CITY, NY / ACCESS Newswire / October 19, 2025 / WHY: New York, N.Y., October 19, 2025. Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Freeport-McMoRan Inc. (NYSE:FCX) resulting from allegations that Freeport may have issued materially misleading business information to

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

(NASDAQ:REPL), WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

(NasdaqGM:RAPT), SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 GlobeNewswire October 19, 2025 WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU) GlobeNewswire October 19, 2025 SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory

Scroll to Top